- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell...
Hence then, the article about xpovio receives reimbursement approval in south korea for a second multiple myeloma indication was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication )
Also on site :
- In 1930, 3 Entrepreneurs Started a Toy Company During the Great Depression; Today, It’s a Household Name
- Steve Madden Started His Shoe Business in 1990 With Just $1,100; 30 Years Later, His Brand Was Selling More Than $1 Billion in Merchandise Annually
- Karen Hale’s mother has lived with breast cancer for nearly 30 years; now the Hales have given $50 million — the largest single gift ever to breast cancer research